TNFRSF17 and neoplasm: This therapy specifically targets the cluster of differentiation (CD) 19 molecule (CD19) or the B-cell maturation antigen (BCMA).1–3 Nevertheless, individuals diagnosed with EMD frequently encounter early recurrence and observe restricted curative outcomes when subjected to CAR-T cell treatment.4,5 There are several potential contributors to this phenomenon, including T cell depletion during in vivo transport, functional impairment of CAR-T cells, and suppression of the tumor microenvironment (TME).